Literature DB >> 16019956

Structural identification of bitespiramycin metabolites in rat: a single oral dose study.

X G Shi1, J P Fawcett, X Y Chen, D F Zhong.   

Abstract

Bitespiramycin is a macrolide antibiotic consisting of a mixture of some nine spiramycin ester derivatives. It has a similar spectrum of antibiotic activity to that of spiramycin but has superior pharmacokinetic properties. In this study, a rapid and facile LC/ESI-MSn method was applied to study the metabolism of bitespiramycin in rat following a single oral dose (80 mg kg-1). Concentrations of parent drug constituents and metabolites were determined in plasma, urine, feces and bile. Concentrations of parent drug constituents and metabolites in plasma were very low. In urine, feces and bile, parent drug constituents and 38 metabolites were identified on the basis of their chromatographic and mass spectrometric properties. The identity of 17 metabolites was confirmed by comparison with reference substances. The principal metabolites were the corresponding spiramycins formed by hydrolysis of the 4''-(3-methylbutanoate) groups. Other important metabolic pathways were: hydrolytic loss of the forosamine and mycarose sugars; aldehyde reduction; cysteine conjugation of the aldehyde group; and hydrolysis of the lactone ring. Products formed by lactone ring opening were found only in urine, and those formed by aldehyde reduction were found only in feces. Aldehyde reduction and hydrolytic loss of forosamine represent novel biotransformation pathways for spiramycin derivatives.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019956     DOI: 10.1080/00498250500087580

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  4 in total

1.  Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.

Authors:  Wai Kit Chew; Ignacio Segarra; Stephen Ambu; Joon Wah Mak
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

2.  Remarkable histopathological improvement of experimental toxoplasmosis after receiving spiramycin-chitosan nanoparticles formulation.

Authors:  Amal Farahat Allam; Nancy Abd-Elkader Hagras; Hoda Fahmy Farag; Mervat Mostafa Osman; Thanaa Ibrahim Shalaby; Amani Hussein Kazem; Amel Youssef Shehab; Nermine Mogahed Fawzy Hussein Mogahed
Journal:  J Parasit Dis       Date:  2021-08-10

3.  Effect of branched-chain amino acids, valine, isoleucine and leucine on the biosythesis of bitespiramycin 4"-O-acylspiramycins.

Authors:  Zhen-Lin Li; Yong-Hong Wang; Ju Chu; Ying-Ping Zhuang; Si-Liang Zhang
Journal:  Braz J Microbiol       Date:  2009-12-01       Impact factor: 2.476

4.  Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.

Authors:  Haiyan Yan; Jing Sun; Kun Wang; Huiqiang Wang; Shuo Wu; Linlin Bao; Weiqing He; Dong Wang; Airu Zhu; Tian Zhang; Rongmei Gao; Biao Dong; Jianrui Li; Lu Yang; Ming Zhong; Qi Lv; Feifei Qin; Zhen Zhuang; Xiaofang Huang; Xinyi Yang; Yuhuan Li; Yongsheng Che; Jiandong Jiang
Journal:  Acta Pharm Sin B       Date:  2021-03-11       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.